

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Chicago, Illinois – March 16, 2024**

<b>Conference Location</b>	<b>Embassy Suites – Magnificent Mile</b> 500 N. Columbus Drive Chicago, IL 60611 (312) 836-5900	<a href="https://www.hilton.com/en/hotels/chirees-embassy-suites-chicago-downtown-magnificent-mile">https://www.hilton.com/en/hotels/chirees-embassy-suites-chicago-downtown-magnificent-mile</a>
<b>Parking and Guest Rooms at the Conference</b>	Self Parking at the hotel is \$50. But try <a href="http://spothero.com">http://spothero.com</a> for nearby rates starting at ~\$15/day  A <b>special guest room rate of \$239</b> is available for Friday evening, March 15 Please book your room by <b>February 24</b>	
<b>Driving Directions</b>	The hotel is located on Columbus Drive, between Illinois St and Grand Avenue, approximately three blocks North of the Chicago River and 3 blocks West of Lakeshore Drive (Highway 41)	

<b>Seminar Agenda and Syllabus Information</b>	Registration begins at <b>7:30 a.m.</b> in the Grand Ballroom, Salons E-F  <b>The Hepatitis and Chronic Liver Disease seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge.
--	---

<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:30 am</b>	<i>Registration and View Exhibits</i>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<b>Advances in the Screening and Treatment of HCV</b> <ul style="list-style-type: none"> <li>Updates on diagnostic approaches</li> <li>Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>Novel FDA Approved Direct Acting Anti-virals</li> <li>Clinical Cases and Discussion</li> </ul>
<b>9:10 am</b>	<b>Hepatitis B: Epidemiology, History, Testing and Treatment</b> <ul style="list-style-type: none"> <li>The epidemiology of the Hepatitis B infection</li> <li>Efficacies and opportunities in HBV testing and vaccination</li> <li>The efficacy of HBV Vaccination and Anti-viral therapies of HBV</li> <li>HBV Re-activation and the Latest studies from EASL and AASLD</li> </ul>
<b>9:40 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>Global and US perspective on the growth of Delta Hepatitis</li> <li>Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>Testing and surveillance approaches</li> <li>Real world outcome studies on HDV and HEV</li> </ul>
<b>10:15 am</b>	<i>Industry Presentation, Break and View exhibits</i>
<b>11:00 am</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>A review of Pre-course lecture on end-stage liver disease</li> <li>Complications of cirrhosis</li> <li>Liver transplant in the era of DAA’s</li> </ul> Clinical cases to illustrate HE, HRS and/or Thrombocytopenia
<b>11:30 am</b>	<b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>Screening diagnostic serum assays and imaging tests</li> <li>Treatment and management options: Ablation, TACE and Surgery</li> </ul>

	<ul style="list-style-type: none"> <li>• New studies showing cost effectiveness of surveillance post SVR</li> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC</li> </ul>
12:00 pm	<b>Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>
12:35 pm	<i>Luncheon and Product Information Session</i>
1:05 pm	<i>Dessert and View Exhibits</i>
1:20 pm	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibanor and the ENHANCE study on seladelpar</li> </ul>
2:05 pm	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>
2:35 pm	<i>Break &amp; View Exhibits</i>
2:50 pm	<b>Steatotic Liver Disease: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
3:25 pm	<b>MASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmitemon</li> </ul> MASH Diagnosis and Treatment case
4:05 pm	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:15 pm
Post-program activities	<b>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome</b> 30 minutes <b>Lecture 4 - Overcoming barriers to liver health in special populations</b> - 30 minutes. <b>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting</b> – 30 minutes

#### Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

#### Attendance Policies

##### Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

##### Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

---

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME  
Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1381. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---

**NANCY REAU, MD, FAASLD**

*Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr. Reau received her undergraduate (B.A.) at Oberlin College in Oberlin Ohio and Doctor of Medicine (M.D.), cum laude, from the Ohio State University in Columbus, Ohio.*

*She completed a medicine residency and a gastroenterology fellowship and did her advanced transplant hepatology fellowship at Johns Hopkins Medical Center.*

*She was employed at Rush University Medical Center in Chicago IL as the Medical Director of hepatology Clinical and Translational.*

*Dr Reau is a fellow of the American Gastroenterological Association and fellow of the American Association*

*n for the Study of Liver Diseases. She has also been the annual honoree of the Illinois chapter of the American Liver Foundation.*

**ANJANA PILLAI, MD**

*Anjana Pillai, MD, is an Associate Professor of Medicine at the University of Chicago Medicine and a board-certified gastroenterologist and transplant hepatologist who specializes in the management of chronic liver disease and hepatobiliary malignancies. Dr. Pillai is the medical director of University of Chicago's multidisciplinary liver tumor program, the medical director of the Adult Living Donor Liver Transplant Program and the Program Director for the ACGME accredited Transplant Hepatology Fellowship.*

*Dr. Pillai is also an active researcher with a focus on hepatocellular carcinoma, cholangiocarcinoma and transplant oncology. In 2019, she co-founded the HCC Therapeutics Targets Conference (HCC-TAG), a national conference that is geared towards bringing clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update on the most relevant advances and challenges in the diagnosis and therapy of HCC*

**Your Seminar  
Faculty****ALLISON MOSER, MSN, FNP-BC**

*Allison Moser is the Solid Organ Transplant Lead APP at Rush University Medical Center, She received her Bachelor of Science in Nursing at the University of Miami in Coral Gables, Florida and Master of Science in Nursing, summa cum laude, from Loyola University Chicago in Maywood, Illinois.*

*Allison's clinical interests include viral hepatitis, hepatocellular carcinoma, and rehabilitation/nutritional therapy. She is involved in research initiatives regarding NASH, Wilson's disease, and hepatic encephalopathy. Allison has been a member of the Illinois Board of Directors for the American Liver Foundation (ALF) and served*

*as co-chair for the Associate Medical Advisory Committee (AMAC). She is currently a member of the American Association for the Study of Liver Diseases (AASLD) Associate Special Interest Group (SIG) and the Illinois Society for Advanced Practice in Nursing (ISAPN).*

---